Jan J Molenaar

Jan J Molenaar

UNVERIFIED PROFILE

Are you Jan J Molenaar?   Register this Author

Register author
Jan J Molenaar

Jan J Molenaar

Publications by authors named "Jan J Molenaar"

Are you Jan J Molenaar?   Register this Author

47Publications

1884Reads

19Profile Views

Neuroblastoma stage 4S: Tumor regression rate and risk factors of progressive disease.

Pediatr Blood Cancer 2019 Nov 17:e28061. Epub 2019 Nov 17.

Princess Máxima Center for Pediatric Oncology, Utrecht, The Netherlands.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/pbc.28061DOI Listing
November 2019

Author Correction: The landscape of genomic alterations across childhood cancers.

Nature 2018 07;559(7714):E10

Hopp-Children's Cancer Center at the NCT Heidelberg (KiTZ), Heidelberg, Germany.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41586-018-0167-2DOI Listing
July 2018

The landscape of genomic alterations across childhood cancers.

Nature 2018 03 28;555(7696):321-327. Epub 2018 Feb 28.

Hopp-Children's Cancer Center at the NCT Heidelberg (KiTZ), Heidelberg, Germany.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/nature25480DOI Listing
March 2018

Cancer Surveillance in Gorlin Syndrome and Rhabdoid Tumor Predisposition Syndrome.

Clin Cancer Res 2017 Jun;23(12):e62-e67

Dana-Farber/Boston Children's Cancer and Blood Disorders Center and Harvard Medical School, Boston, Massachusetts.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-17-0595DOI Listing
June 2017

Enhancer of zeste homologue 2 plays an important role in neuroblastoma cell survival independent of its histone methyltransferase activity.

Eur J Cancer 2017 04 17;75:63-72. Epub 2017 Feb 17.

Department of Translational Medicine, Prinses Máxima Center for Pediatric Oncology, Utrecht, The Netherlands. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ejca.2016.12.019DOI Listing
April 2017

DNA-Dependent Protein Kinase As Molecular Target for Radiosensitization of Neuroblastoma Cells.

PLoS One 2015 30;10(12):e0145744. Epub 2015 Dec 30.

Department of Oncogenomics, Academic Medical Center, University of Amsterdam, Amsterdam, the Netherlands.

View Article

Download full-text PDF

Source
http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0145744PLOS
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4696738PMC
June 2016

TERT rearrangements are frequent in neuroblastoma and identify aggressive tumors.

Nat Genet 2015 Dec 2;47(12):1411-4. Epub 2015 Nov 2.

Department of Oncogenomics, Academic Medical Center, Amsterdam, the Netherlands.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/ng.3438DOI Listing
December 2015

Towards personalized therapy in pediatric acute lymphoblastic leukemia: RAS mutations and prednisolone resistance.

Haematologica 2015 Apr 5;100(4):e132-6. Epub 2014 Dec 5.

Department of Pediatric Oncology/Hematology, Erasmus Medical Center-Sophia Children's Hospital, Rotterdam Individualized Therapies for Children with Cancer Study Group Dutch Childhood Oncology Group, The Hague, The Netherlands

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3324/haematol.2014.112995DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4380734PMC
April 2015

miR-542-3p exerts tumor suppressive functions in neuroblastoma by downregulating Survivin.

Int J Cancer 2015 Mar 5;136(6):1308-20. Epub 2014 Aug 5.

Department of Pediatric Oncology and Hematology, University Children's Hospital Essen, Essen, Germany; German Cancer Consortium (DKTK), Germany.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/ijc.29091DOI Listing
March 2015

Whole-genome sequencing identifies patient-specific DNA minimal residual disease markers in neuroblastoma.

J Mol Diagn 2015 Jan 24;17(1):43-52. Epub 2014 Oct 24.

Landsteiner Laboratory, Department of Pediatric Oncology, Emma Children's Hospital, Academical Medical Center, University of Amsterdam, Amsterdam, the Netherlands. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jmoldx.2014.09.005DOI Listing
January 2015

Liquid chromatography-tandem mass spectrometric assay for the light sensitive survivin suppressant sepantronium bromide (YM155) in mouse plasma.

J Pharm Biomed Anal 2014 Apr 21;92:144-8. Epub 2014 Jan 21.

Utrecht University, Faculty of Science, Department of Pharmaceutical Sciences, Division of Pharmacoepidemiology & Clinical Pharmacology, Universiteitsweg 99, 3584 CG Utrecht, The Netherlands. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jpba.2014.01.011DOI Listing
April 2014

Newly-derived neuroblastoma cell lines propagated in serum-free media recapitulate the genotype and phenotype of primary neuroblastoma tumours.

Eur J Cancer 2014 Feb 6;50(3):628-37. Epub 2013 Dec 6.

Department of Oncogenomics, Academic Medical Center, University of Amsterdam, Meibergdreef 15, PO Box 22700, 1105 AZ Amsterdam, The Netherlands. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ejca.2013.11.015DOI Listing
February 2014

Liquid chromatography-tandem mass spectrometric assay for the cyclin-dependent kinase inhibitor AT7519 in mouse plasma.

J Pharm Biomed Anal 2014 Jan 12;88:216-20. Epub 2013 Sep 12.

Amsterdam Medical Center, University of Amsterdam, Department of Oncogenomics, Meibergdreef 15, PO Box 22700, 1105 AZ Amsterdam, The Netherlands.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jpba.2013.08.051DOI Listing
January 2014

Prevalence and clinical implications of chromothripsis in cancer genomes.

Curr Opin Oncol 2014 Jan;26(1):64-72

aDepartment of Medical Genetics, University Medical Center Utrecht, Utrecht bDepartment of Oncogenomics, Academic Medical Center, Amsterdam, The Netherlands.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/CCO.0000000000000038DOI Listing
January 2014

Targeted BCL2 inhibition effectively inhibits neuroblastoma tumour growth.

Eur J Cancer 2012 Nov 25;48(16):3093-103. Epub 2012 Feb 25.

Department of Oncogenomics, Academic Medical Center, University of Amsterdam, Meibergdreef 15, PO Box 22700, 1105 AZ Amsterdam, The Netherlands.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ejca.2012.01.037DOI Listing
November 2012

Functional MYCN signature predicts outcome of neuroblastoma irrespective of MYCN amplification.

Proc Natl Acad Sci U S A 2012 Nov 22;109(47):19190-5. Epub 2012 Oct 22.

Department of Oncogenomics, Academic Medical Center, University of Amsterdam, Meibergdreef 9, 1105 AZ Amsterdam, The Netherlands.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1073/pnas.1208215109DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3511149PMC
November 2012

Identification of BIRC6 as a novel intervention target for neuroblastoma therapy.

BMC Cancer 2012 Jul 12;12:285. Epub 2012 Jul 12.

Department of Oncogenomics, Academic Medical Center, University of Amsterdam, Meibergdreef 15, PO box 22700, Amsterdam, AZ 1105, The Netherlands.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/1471-2407-12-285DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3495678PMC
July 2012

Targeted BIRC5 silencing using YM155 causes cell death in neuroblastoma cells with low ABCB1 expression.

Eur J Cancer 2012 Mar 14;48(5):763-71. Epub 2011 Nov 14.

Department of Oncogenomics, Academic Medical Center, University of Amsterdam, Meibergdreef 15, PO Box 22700, 1105 AZ Amsterdam, The Netherlands.

View Article

Download full-text PDF

Source
http://linkinghub.elsevier.com/retrieve/pii/S095980491100799
Publisher Site
http://dx.doi.org/10.1016/j.ejca.2011.10.012DOI Listing
March 2012

Neuroblastoma therapy: what is in the pipeline?

Endocr Relat Cancer 2011 Dec 14;18(6):R213-31. Epub 2011 Nov 14.

Division of Medical Pharmacology, Leiden/Amsterdam Center for Drug Research, Leiden University Medical Center, Gorlaeus Laboratories, The Netherlands.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1530/ERC-11-0251DOI Listing
December 2011

Knockdown of survivin (BIRC5) causes apoptosis in neuroblastoma via mitotic catastrophe.

Endocr Relat Cancer 2011 Oct 27;18(6):657-68. Epub 2011 Oct 27.

Department of Oncogenomics, Academic Medical Center, University of Amsterdam, Meibergdreef 15, PO Box 22700, 1105 AZ Amsterdam, The Netherlands.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1530/ERC-11-0207DOI Listing
October 2011

Inactivation of CDK2 is synthetically lethal to MYCN over-expressing cancer cells.

Proc Natl Acad Sci U S A 2009 Aug 12;106(31):12968-73. Epub 2009 Jun 12.

Department of Human Genetics, Academic Medical Center, Department of Pediatric Oncology, Emma Kinderziekenhuis, Academic Medical Center, University of Amsterdam, Meibergdreef 15, PO box 22700, 1105 AZ Amsterdam, The Netherlands.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1073/pnas.0901418106DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2695754PMC
August 2009

Cyclin D1 and CDK4 activity contribute to the undifferentiated phenotype in neuroblastoma.

Cancer Res 2008 Apr;68(8):2599-609

Department of Human Genetics, Academic Medical Center, University of Amsterdam, Amsterdam, the Netherlands.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/0008-5472.CAN-07-5032DOI Listing
April 2008

Rearrangements and increased expression of cyclin D1 (CCND1) in neuroblastoma.

Genes Chromosomes Cancer 2003 Mar;36(3):242-9

Department of Human Genetics, Academic Medical Centre, University of Amsterdam, Amsterdam, The Netherlands.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/gcc.10166DOI Listing
March 2003